GB201205642D0 - Vesicular formulations - Google Patents

Vesicular formulations

Info

Publication number
GB201205642D0
GB201205642D0 GBGB1205642.0A GB201205642A GB201205642D0 GB 201205642 D0 GB201205642 D0 GB 201205642D0 GB 201205642 A GB201205642 A GB 201205642A GB 201205642 D0 GB201205642 D0 GB 201205642D0
Authority
GB
United Kingdom
Prior art keywords
vesicular formulations
vesicular
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1205642.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequessome Technology Holdings Ltd
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Priority to GBGB1205642.0A priority Critical patent/GB201205642D0/en
Publication of GB201205642D0 publication Critical patent/GB201205642D0/en
Priority to AU2013241701A priority patent/AU2013241701A1/en
Priority to SG11201406144TA priority patent/SG11201406144TA/en
Priority to EA201491581A priority patent/EA038899B1/ru
Priority to IN7913DEN2014 priority patent/IN2014DN07913A/en
Priority to CN201380027033.9A priority patent/CN104349782A/zh
Priority to PCT/EP2013/056694 priority patent/WO2013144289A1/en
Priority to EP13712801.3A priority patent/EP2830630A1/en
Priority to NZ700472A priority patent/NZ700472A/en
Priority to US14/388,469 priority patent/US9555051B2/en
Priority to MX2014011516A priority patent/MX2014011516A/es
Priority to JP2015502351A priority patent/JP2015511618A/ja
Priority to BR112014024033A priority patent/BR112014024033A8/pt
Priority to KR1020147027498A priority patent/KR20150004798A/ko
Priority to CA2867749A priority patent/CA2867749A1/en
Priority to GB1419075.5A priority patent/GB2515440B/en
Priority to PH12014502065A priority patent/PH12014502065A1/en
Priority to IL234747A priority patent/IL234747A0/en
Priority to CL2014002547A priority patent/CL2014002547A1/es
Priority to CO14238690A priority patent/CO7121334A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)
GBGB1205642.0A 2012-03-29 2012-03-29 Vesicular formulations Ceased GB201205642D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
GB1419075.5A GB2515440B (en) 2012-03-29 2013-03-28 Vesicular Formulations for use in the treatment of Rosacea
NZ700472A NZ700472A (en) 2012-03-29 2013-03-28 Use of vesicular formations in the manufacture of a medicament for treating rosacea
MX2014011516A MX2014011516A (es) 2012-03-29 2013-03-28 Formulaciones vesiculares.
EA201491581A EA038899B1 (ru) 2012-03-29 2013-03-28 Везикулярные композиции
IN7913DEN2014 IN2014DN07913A (enExample) 2012-03-29 2013-03-28
CN201380027033.9A CN104349782A (zh) 2012-03-29 2013-03-28 囊泡制剂
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations
EP13712801.3A EP2830630A1 (en) 2012-03-29 2013-03-28 Vesicular formulations
AU2013241701A AU2013241701A1 (en) 2012-03-29 2013-03-28 Vesicular formulations
US14/388,469 US9555051B2 (en) 2012-03-29 2013-03-28 Vesicular formulations
SG11201406144TA SG11201406144TA (en) 2012-03-29 2013-03-28 Vesicular formulations
JP2015502351A JP2015511618A (ja) 2012-03-29 2013-03-28 小胞製剤
BR112014024033A BR112014024033A8 (pt) 2012-03-29 2013-03-28 Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
KR1020147027498A KR20150004798A (ko) 2012-03-29 2013-03-28 소포성 제형
CA2867749A CA2867749A1 (en) 2012-03-29 2013-03-28 Vesicular formulations
PH12014502065A PH12014502065A1 (en) 2012-03-29 2014-09-17 Vesicular formulations
IL234747A IL234747A0 (en) 2012-03-29 2014-09-18 Vascular formulations
CL2014002547A CL2014002547A1 (es) 2012-03-29 2014-09-25 Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea.
CO14238690A CO7121334A2 (es) 2012-03-29 2014-10-28 Formulaciones vesiculares

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations

Publications (1)

Publication Number Publication Date
GB201205642D0 true GB201205642D0 (en) 2012-05-16

Family

ID=46159988

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1205642.0A Ceased GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
GB1419075.5A Expired - Fee Related GB2515440B (en) 2012-03-29 2013-03-28 Vesicular Formulations for use in the treatment of Rosacea

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1419075.5A Expired - Fee Related GB2515440B (en) 2012-03-29 2013-03-28 Vesicular Formulations for use in the treatment of Rosacea

Country Status (19)

Country Link
US (1) US9555051B2 (enExample)
EP (1) EP2830630A1 (enExample)
JP (1) JP2015511618A (enExample)
KR (1) KR20150004798A (enExample)
CN (1) CN104349782A (enExample)
AU (1) AU2013241701A1 (enExample)
BR (1) BR112014024033A8 (enExample)
CA (1) CA2867749A1 (enExample)
CL (1) CL2014002547A1 (enExample)
CO (1) CO7121334A2 (enExample)
EA (1) EA038899B1 (enExample)
GB (2) GB201205642D0 (enExample)
IL (1) IL234747A0 (enExample)
IN (1) IN2014DN07913A (enExample)
MX (1) MX2014011516A (enExample)
NZ (1) NZ700472A (enExample)
PH (1) PH12014502065A1 (enExample)
SG (1) SG11201406144TA (enExample)
WO (1) WO2013144289A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
BR112017013471A2 (pt) * 2014-12-23 2018-02-27 Camurus Ab Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
DK3316857T3 (da) 2015-06-30 2021-10-18 Sequessome Tech Holdings Limited Multifasiske sammensætninger
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US20240299378A1 (en) * 2021-02-25 2024-09-12 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JP3765579B2 (ja) 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
AU4327193A (en) 1992-07-08 1994-01-31 Dianorm-Gerate G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
WO1999025332A1 (de) * 1997-11-19 1999-05-27 Schering Aktiengesellschaft Zusammensetzung mit azelainsäure
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CN1322129A (zh) 1998-09-01 2001-11-14 伊迪亚股份公司 带电穿透剂通过屏障的电控转运
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
ES2280355T3 (es) 2000-04-12 2007-09-16 Liplasome Pharma A/S Sistema de administracion de medicamentos basados en lipidos para su utilizacion en la piel.
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
CA2448627A1 (en) 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
JP2004535434A (ja) 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
KR101076335B1 (ko) 2002-03-13 2011-10-26 토마스 스쾰트 수성-기재 전달계
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
ATE381316T1 (de) 2002-10-11 2008-01-15 Idea Ag Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässigen barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut
AU2004235781A1 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
AU2004257375A1 (en) 2003-07-21 2005-01-27 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
JP2005179313A (ja) * 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
JP2008519784A (ja) 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
AP2626A (en) 2005-08-29 2013-03-26 Sepsicure Llc Method for treatment or prevention of conditions caused by gram-positive bacteria
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
JP5009547B2 (ja) * 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
CN101541308B (zh) 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
MX2011008204A (es) 2009-02-05 2011-12-06 Targeted Delivery Technologies Ltd Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
CN114949237A (zh) 2013-07-31 2022-08-30 斯昆申技术控股有限责任公司 囊泡

Also Published As

Publication number Publication date
CL2014002547A1 (es) 2015-03-27
GB2515440B (en) 2017-02-08
GB2515440A (en) 2014-12-24
IN2014DN07913A (enExample) 2015-04-24
GB201419075D0 (en) 2014-12-10
PH12014502065A1 (en) 2014-12-10
NZ700472A (en) 2016-02-26
SG11201406144TA (en) 2014-10-30
CO7121334A2 (es) 2014-11-20
IL234747A0 (en) 2014-11-30
MX2014011516A (es) 2015-04-08
JP2015511618A (ja) 2015-04-20
BR112014024033A8 (pt) 2017-07-25
EA038899B1 (ru) 2021-11-03
US9555051B2 (en) 2017-01-31
WO2013144289A1 (en) 2013-10-03
EP2830630A1 (en) 2015-02-04
US20150057249A1 (en) 2015-02-26
AU2013241701A1 (en) 2014-10-16
CA2867749A1 (en) 2013-10-03
KR20150004798A (ko) 2015-01-13
EA201491581A1 (ru) 2015-02-27
CN104349782A (zh) 2015-02-11
BR112014024033A2 (enExample) 2017-06-20

Similar Documents

Publication Publication Date Title
TWI563077B (en) Cleaning formulations
PL2877155T3 (pl) Formulacje opioidowe
IL289157A (en) Opioid compounds
SI2614812T1 (sl) Ustna vodica
HUE071706T2 (hu) Triazin készítmények
IL234747A0 (en) Vascular formulations
ZA201408114B (en) Oral formulation
PL2908859T3 (pl) Formulacje arypiprazolu
GB201110278D0 (en) Formulations
GB201219112D0 (en) Brush
GB201206178D0 (en) Formulations
GB201200343D0 (en) Combined toothbrush
AU347722S (en) Toothbrush
PH32012000443S1 (en) Toothbrush
PH32012000346S1 (en) Toothbrush
PH32012000345S1 (en) Toothbrush
PH32012000133S1 (en) Toothbrush
PH32012000132S1 (en) Toothbrush
PH32012000134S1 (en) Toothbrush
PH32012000135S1 (en) Toothbrush
PH32012000126S1 (en) Toothbrush
PH32012000127S1 (en) Toothbrush
PH32012000128S1 (en) Toothbrush
GB201211795D0 (en) Angled toothbrush
GB201107626D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S30Z Assignments for licence or security reasons

Free format text: APPLICANT. SEQUESSOME TECHNOLOGY HOLDIGS LIMITED SECURITY INTEREST. FONDS RUSNANO CAPITAL S.A.